SNDX - Syndax Pharmaceuticals, Inc.
About Syndax Pharmaceuticals, Inc. (https://www.syndax.com)
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael A. Metzger | Chief Executive Officer & Director | 1971 | $1,612,888 USD |
| Nicholas Botwood MBBS | Head of Research & Development and Chief Medical Officer | 1968 | $876,846 USD |
| Keith Alan Goldan | CFO, Treasurer & Principal Accounting Officer | 1971 | $852,548 USD |
| Luke J. Albrecht | Senior Vice President, General Counsel & Secretary | 1979 | $842,308 USD |
| Steven Closter | Chief Commercial Officer | 1969 | $822,878 USD |
| Michael Downes | Co-Founder | – | – |
| Peter Ordentlich | Co-Founder & Chief Scientific Officer | 1969 | – |
| Richard A. Heyman | Co-Founder | 1957 | – |
| Ronald Evans | Co-Founder, Advisor and Chair of Scientific Advisory Board | 1950 | – |
| Sharon Klahre | Vice President of Investor Relations & Communications | – | – |